凝血与免疫疗法和BRAF/MEK抑制剂治疗的相互依赖:从前性研究中得出的结果
Malte Beckmann1, Julian Schlüter2, Michael Erdmann1
1Department of Dermatology, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), University Hospital Erlangen, Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nuremberg (FAU), 91054, Erlangen, Germany.
Cancer immunology, immunotherapy : CII
|November 2, 2024
概括
免疫检查点抑制剂 (ICI) 和BRAF/MEK抑制剂可以诱导前凝血状态,增加复发风险. 凝血参数可能会影响ICI治疗在晚期皮肤癌患者的有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 免疫检查点抑制剂 (ICI) 治疗各种癌症,但可能导致与免疫相关的副作用.
- 癌症患者面临更高的血栓栓塞事件的风险.
- 系统性疗法可能会诱导促凝效应,可能会影响抗瘤反应和疗效.
研究的目的:
- 研究系统性瘤疗法诱导的促凝效应的机制.
- 分析凝血参数与抗瘤反应之间的相互作用.
- 评估凝血变化对患者生存结果的影响.
主要方法:
- 在31名晚期皮肤癌患者中对血液和凝血参数的纵向评估.
- 用ICI (n=24) 和BRAF/MEK抑制剂 (n=7) 治疗的患者之间的变化比较.
- 分析凝血参数对无进展,无复发和整体存活时间的影响.
主要成果:
- ICI治疗显著增加了XIII因子活性,并降低了蛋白S活性.
- 在免疫疗法下,·维勒布兰德因子活性和组织因子度增加.
- 基线威尔布兰德因子抗原和因子VIII:C的增加与辅助免疫疗法中复发风险更高相关.
结论:
- 系统性瘤疗法,包括ICI和BRAF/MEKi,诱导一个前凝固状态.
- 凝血参数对ICI疗法的疗效起着重要作用.
- 基线凝血标记可以预测在接受辅助免疫治疗的患者中复发风险.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
484
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
484


